

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2025	Preceding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
	Income				
1	Revenue from operations	80483	96608	81100	372349
2	Other income	4376	3946	3585	14256
3	Total Income (1+2)	84859	100554	84685	386605
	Expenses				
	(a) Cost of materials consumed	12143	10835	13333	47086
	(b) Purchases of stock-in-trade	23207	29140	17274	84511
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(6553)	(5341)	(1326)	5123
	(d) Employee benefits expense	15257	15297	15128	57970
	(e) Finance costs	42	58	37	131
	(f) Depreciation and amortisation expense	1552	1472	1641	6679
	(g) Other expenses	11354	13603	13749	60730
4	Total expenses	57002	65064	59836	262230
5	Profit before exceptional items and tax (3-4)	27857	35490	24849	124375
6	Exceptional items (credit) (Refer Note 4)	-	-	-	469
7	Profit before tax (5+6)	27857	35490	24849	124844
8	Tax expense				
	(a) Current tax	7385	8934	6333	32318
	(b) Deferred tax	2	542	351	620
9	Profit for the period/year (7-8)	20470	26014	18165	91906

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025


(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2025 (Unaudited)	Preceeding 3 months ended 31.03.2025 (Unaudited) (Refer Note 2)	Corresponding 3 months ended 30.06.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
10	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(512)	-	(355)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	128	-	89
11	Total comprehensive income for the period (9+10)	20470	25630	18165	91640
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				177982
	Earnings per share (EPS) (of Rs. 10 each)				
	Basic and diluted EPS before Exceptional items (Rs.)	12.08	15.35	10.72	54.01
	Basic and diluted EPS after Exceptional items (Rs.)	12.08	15.35	10.72	54.24
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 01st August 2025. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June 2025.
2. The figures for the 3 months ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2025.
3. Final dividend of Rs. 42 per equity share for the year ended 31st March 2025 had been approved by the shareholders in the Annual General meeting held on 27th June 2025.
4. Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties
5. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

01st August, 2025

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

Particulars	3 months ended 30.06.2025	Preceding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
Income				
Revenue from operations	80517	97437	81465	374921
Other income	4372	4068	3564	14593
Total Income (1+2)	84889	101505	85029	389514
Expenses				
(a) Cost of materials consumed	12806	11523	13823	49990
(b) Purchases of stock-in-trade	23206	29140	17274	84511
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(7241)	(5469)	(1570)	4585
(d) Employee benefits expense	15257	15297	15128	57970
(e) Finance costs	42	58	37	131
(f) Depreciation and amortisation expense	1552	1472	1641	6679
(g) Other expenses	11369	13627	13756	60129
Total expenses	56991	65648	60089	263995
Profit before exceptional items and tax (3-4)	27898	35857	24940	125519
Exceptional items (credit) (Refer Note 4)	-	-	-	469
Profit before tax (5+6)	27898	35857	24940	125988
Tax expense				
(a) Current tax	7395	9015	6356	32596
(b) Deferred tax	2	555	351	634
Profit for the period/year (7-8)	20501	26287	18233	92758

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)


Particulars	3 months ended 30.06.2025	Preceding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
0 Other comprehensive income				
(i) Items that will not be reclassified to profit or loss	-	(512)	-	(355)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	128	-	89
1 Total comprehensive income for the period (9+10)	20501	25903	18233	92492
2 Total comprehensive income for the period attributable to owners of the Group	20501	25903	18233	92492
Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
Other equity				178190
Earnings per share (EPS) (of Rs. 10 each)				
Basic and diluted EPS before Exceptional items (Rs.)	12.10	15.52	10.76	54.52
Basic and diluted EPS after Exceptional items (Rs.)	12.10	15.52	10.76	54.76
	Not Annualised			

Notes:

- . The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 01st August 2025. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June 2025.
- . The figures for the 3 months ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2025.
- . Final dividend of Rs. 42 per equity share for the year ended 31st March 2025 had been approved by the shareholders in the Annual General meeting held on 27th June 2025.
- . Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties.
- . The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

01st August, 2025

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346